A groundbreaking study published in the journal Addiction reveals that Ozempic (semaglutide) and similar medications may significantly reduce alcohol and opioid addiction.
Key Findings:
- 40% reduction in opioid overdose rates among individuals with opioid use disorder (OUD) taking Ozempic or similar medications.
- 50% reduction in alcohol intoxication among individuals with alcohol use disorder (AUD) taking Ozempic or similar medications.
How it Works:
Ozempic, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), interacts with the brain’s mesolimbic system, reducing appetite and triggering satisfaction. This overlap with brain processes governing addictive behaviors suggests potential for treating substance use disorders.
Expert Insights:
“This study introduces a promising new treatment for substance use disorders… GLP-1 RAs and GIPs may alter reward-response pathways associated with substance use.” – Study Authors
Reference:
Qeadan, F., McCunn, A., & Tingey, B. (2024). The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. DOI: 10.1111/add.16679
Share Your Thoughts:
How can this discovery impact addiction treatment? What role should medications like Ozempic play in addressing the opioid and alcohol crises?
Related Articles:
- Study Finds No Evidence to Suggest Cannabis Helps Patients Stop Using Opioids
- Opioid Prescription Doses Are Often Being Tapered More Rapidly Than Recommended
- Stemming the Opioid Crisis: New Addiction Treatments Hold Promise
